期刊
FUTURE MEDICINAL CHEMISTRY
卷 11, 期 4, 页码 269-284出版社
FUTURE SCI LTD
DOI: 10.4155/fmc-2018-0511
关键词
anticancer efficacy; chloroethylnitrosoureas; hypoxia-activated prodrug; O-6-Alkylguanine DNA alkyltransferase inhibition; tumor targeting
资金
- National Natural Science Foundation of China [21778011]
- Beijing Natural Science Foundation [7162015, 7184192]
- China Postdoctoral Science Foundation [2017M620567]
- Beijing Postdoctoral Research Foundation [2018-ZZ-022]
- Education Commission Science and Technology Project of Beijing Municipality [PXM2015 014204 500175]
- Great Wall scholars program of Beijing Municipal Education Commission [CITTCD20180308]
Aim: A hypoxia-activated combi-nitrosourea prodrug, N-(2-chloroethyl)-N'-2-(2-(4-nitrobenzylcarbamate)-O-6-benzyl-9-guanine)ethyl-N-nitrosourea (NBGNU), was synthesized and evaluated for its hypoxic selectivity and anticancer activity in vitro. Results: The prodrug was designed as a tripartite molecule consisting of a chloroethylnitrosourea pharmacophore to induce DNA interstrand crosslinks (ICLs) and an O-6-benzylguanine analog moiety masked by a 4-nitrobenzylcarbamate group to induce hypoxia-activated inhibition of O-6-alkylguanine-DNA alkyltransferase. NBGNU was tested for hypoxic selectivity, cytotoxicity and DNA ICLs ability. The reduction product amounts, cell death rates and DNA ICL levels induced by NBGNU under hypoxic conditions were all significantly higher than those induced by NBGNU under normoxic conditions. Conclusion: The tripartite combi-nitrosourea prodrug exhibits desirable tumor-hypoxia targeting ability and abolished chemoresistance compared with the conventional chloroethylnitrosoureas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据